United Therapeutics announced that the New England Journal of Medicine published the full results of its Phase 3 TETON‑2 study on March 11, 2026. The study evaluated nebulized Tyvaso in patients with idiopathic pulmonary fibrosis and met its primary efficacy endpoint, showing a statistically significant improvement in absolute forced vital capacity (FVC) compared with placebo.
The benefit was consistent across all patient subgroups, indicating that nebulized Tyvaso preserves lung function regardless of baseline disease severity. The primary endpoint was a change in absolute FVC, and the study also demonstrated a statistically significant improvement in time to clinical worsening, underscoring the drug’s potential to alter disease progression.
These findings support a potential label expansion into the IPF market, which could open a new revenue stream for United Therapeutics and reinforce its strategy to broaden the therapeutic reach of its treprostinil franchise. If approved, Tyvaso would become the first inhaled anti‑fibrotic treatment for IPF, a market estimated to exceed $4 billion in the United States alone.
Peter Smith, Senior Vice President of Product Development, said the results “confirm our hypothesis that nebulized Tyvaso can transform IPF treatment and could serve as a first‑line inhaled therapy.” He added that the study “met its primary endpoint and achieved statistical significance for time to clinical worsening.” Chairperson and CEO Martine Rothblatt noted that the data “unlock hope for patients with IPF and their families.”
Analysts have responded positively to the data, raising price targets in the wake of the publication. UBS increased its target to $705 on March 5, 2026, and Cantor Fitzgerald lifted its target to $625 on March 12, citing the TETON‑1 trial and the IPF narrative as key drivers of optimism.
United Therapeutics plans to submit a supplemental New Drug Application to the FDA in the second half of 2026, contingent on the results of the ongoing TETON‑1 study, which is expected to report in the first half of 2026. The company’s strategy is to use the TETON‑2 data to accelerate regulatory discussions and, if approved, launch nebulized Tyvaso for IPF, potentially adding significant revenue to its portfolio in the coming years.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.